Dindigul Farm Product Limited board approved an application to the Central Government for the continuation of R Rajasekaran as Managing Director beyond the age of 70 years.

The decision, taken during a meeting held on October 9, 2026, also authorised an interim change in designation. Rajasekaran will serve as Non-Executive Chairman until the Central Government grants the necessary approval for his continued tenure as Managing Director.

Governance and regulatory compliance

The board meeting commenced at 12:45 pm and concluded at 1:15 pm. The company filed this outcome with BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The application addresses statutory requirements regarding the age limit for Managing Directors. By seeking government approval, the company aims to retain leadership continuity while adhering to corporate governance norms.

Key board decisions

• Application Filing: The board resolved to file an application before the Central Government seeking approval for R Rajasekaran to continue as Managing Director after attaining the age of 70 years.
• Interim Designation Change: The board approved changing Rajasekaran's designation from Chairman and Managing Director to Non-Executive Chairman. This change remains effective up to the receipt of the Central Government's approval.

The Company Secretary and Compliance Officer, G U K Narayanan, signed the disclosure digitally on October 9, 2026.

Dindigul Farm Product Limited has informed the Bombay Stock Exchange (BSE) that its promoter, Indrayani Biotech Limited, disposed of 4,48,000 equity shares on September 30, 2026, without submitting the required Form C disclosure.

The company identified the transaction through its Registrar and Share Transfer Agent (RTA) share transaction report. Upon verification, Dindigul Farm Product noted the absence of prior intimation or regulatory disclosure from the promoter entity regarding this specific disposal.

Regulatory non-compliance details

The company sent an email to Indrayani Biotech Limited on October 5, 2026, seeking an explanation and requesting submission of the requisite Form C and pre-clearance documentation. This action was taken in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct.

Indrayani Biotech’s Company Secretary responded on October 6, 2026, stating that Form C would be submitted by the end of the day on October 7, 2026. However, as of the date of the intimation to BSE, the disclosure document had not been received.

Transaction specifics

The company stated it will take appropriate further action in accordance with applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, including Regulation 7(2), and other relevant regulatory requirements.